Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lockhart

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Annals of the Rheumatic Diseases|December 25, 2015
Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathologyCarmen Huesa, Ana C Ortiz, Lynette Dunning, et al.
Cancer Research|October 10, 2024
Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate CancerLing Zhang, Clara I Troccoli, Beatriz Mateo-Victoriano, et al.
Contemporary Clinical Trials|July 9, 2010
Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB)Yaffa R Rubinstein, Stephen C Groft, Ronald Bartek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced MalignanciesKyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colonBrian G Czito, Timothy J Hong, Darrel P Cohen, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal CancerHiroyuki Arai, Andrew Elliott, Joanne Xiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2023
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Annals of the Rheumatic Diseases|December 25, 2015
Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathologyCarmen Huesa, Ana C Ortiz, Lynette Dunning, et al.
Cancer Research|October 10, 2024
Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate CancerLing Zhang, Clara I Troccoli, Beatriz Mateo-Victoriano, et al.
Contemporary Clinical Trials|July 9, 2010
Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB)Yaffa R Rubinstein, Stephen C Groft, Ronald Bartek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced MalignanciesKyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colonBrian G Czito, Timothy J Hong, Darrel P Cohen, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal CancerHiroyuki Arai, Andrew Elliott, Joanne Xiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2023
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Pageof 14